Book a Meeting

Fc Engineered Anti-Human EGFR Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ09] (CAT#: BioBet-C009ZP) Datasheet

Human Antibody
CDC-enhanced Necitumumab is a Fc-modified anti-EGFR therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Necitumumab, the Fc region of Necitumumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Metastatic Colorectal Cancer (MCRC)
Metastatic Squamous Cell Carcinoma of the Head and Neck
Advanced squamous cell carcinoma of the head and neck
Therapeutic antibody; biobetter
Not Available

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Necitumumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Full Name
epidermal growth factor receptor
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer.
Alternative Names
EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Gene ID
UniProt ID
Trade name
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB09559 (DB05774)
CAS number
Antibody Isotype
Human IgG1
Necitumumab (INN), trade name Portrazza, is a recombinant human IgG1 monoclonal antibody used as an antitumor drug. It acts as an EGFR antagonist and binds to the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC). Necitumumab approved by the US FDA for previously untreated metastatic squamous non-small cell lung cancer (NSCLC).
Metastatic Non-Small Cell Lung Cancer
Not Available

Necitumumab is an EGFR antagonist that works by binding to the epidermal growth factor receptor (EGFR) and preventing its ligand from binding and is widely used to treat metastatic NSCLC. The binding of necitumumab to EGFR can induce receptor internalization and degradation. In vivo data in mouse model show that Necitumumab can target tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and increase antitumor activity.

Necitumumab is approved as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC) with cisplatin and gemcitabine.
Solide Tumors
Metastatic Non-Small Cell Lung Cancer

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *